Trials / Terminated
TerminatedNCT00995605
AMAP102 - Safety, Tolerability and Pharmacokinetics in Healthy Subjects
AMAP102 - A Phase I, Double-Blind, Placebo-Controlled, Single and Multiple Oral Dose, Safety, Tolerability and Pharmacokinetics Study in Healthy Subjects
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- AnaMar AB · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to determine whether AMAP102 is safe and well tolerated by humans.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AMAP102 | AMAP102 or Placebo |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2009-08-01
- Completion
- 2009-08-01
- First posted
- 2009-10-15
- Last updated
- 2009-10-15
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT00995605. Inclusion in this directory is not an endorsement.